Method for assessing heart disease
AssigneeThe Cleveland Clinic Foundation
InventorsSathyamangla V. Naga Prasad, Sadashiva Karnik, Carlo Croce, Dianne M. Perez, Edward Plow, Christine Moravec, Subha Sen, Qingyu Wu, Randall C. Starling
Life of this patent
Estimating the term…
Abstract
A method for assessing heart disease in a subject includes generating an expression profile of at least two or more miRNAs in a sample from the subject. The miRNAs can be selected from the group consisting of hsa-miRNA-1, hsa-miRNA-7, hsa-miRNA-29b, has-miRNA-125b, hsa-miRNA145, hsa-miRNA-181b, hsa-miRNA-214, hsa-miRNA-342, hsa-miRNA-378 and combinations thereof.
Claims20
A method for assessing heart disease in a subject comprising:
- obtaining a biological sample from the subject that includes miRNA;
- measuring the expression level of at least two miRNAs in the sample, the miRNAs selected from the group consisting of hsa-miRNA-1, hsa-miRNA-7, has-miRNA-29b, hsa-miRNA-125b, hsa-miRNA-145, hsa-miRNA-181b, hsa-miRNA-214, hsa-miRNA-342, hsa-miRNA-378 and combinations thereof;
- and
- comparing the expression level of the at least two miRNAs to a control expression level, wherein a difference in the expression level of the sample from the subject and the control expression level is indicative of heart disease.
A method for assessing heart disease in a subject comprising:
- obtaining a sample of peripheral blood mononuclear cells from the subject;
- measuring expression levels of at least one miRNA associated with heart disease from the peripheral blood mononuclear cell sample, wherein the expression of the at least one miRNA from the peripheral blood mononuclear cell sample corresponds to miRNA expression level in the subject's myocardial tissue;
- and
- comparing the expression levels of the measured miRNA to a control expression level, wherein a difference in the measured expression level and the control expression level is indicative of heart disease.
A method for assessing heart disease in a subject comprising:
- obtaining a sample of peripheral blood mononuclear cells from the subject;
- measuring the expression level of at least two miRNAs in the sample, the miRNAs selected from the group consisting of hsa-miRNA-1, hsa-miRNA-7, has-miRNA-29b, hsa-miRNA-125b, hsa-miRNA-145, hsa-miRNA-181b, hsa-miRNA-214, has-miRNA-342, hsa-miRNA-378 and combinations thereof;
- and
- comparing the expression level of the at least two or more miRNAs to a control expression level, wherein a difference in the expression level of the sample from the subject and the control expression level is indicative of heart disease.
Dependencies are inferred from the claim text.